Alector, Inc. Files Q1 2025 10-Q
Ticker: ALEC · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotechnology
TL;DR
Alector's Q1 2025 10-Q is in. Check financials.
AI Summary
Alector, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported on its financial activities. Key financial data points and disclosures related to its operations and financial instruments are included in this filing.
Why It Matters
This filing provides investors and analysts with a quarterly update on Alector's financial health and operational performance, crucial for understanding the company's trajectory in the biotechnology sector.
Risk Assessment
Risk Level: medium — Biotechnology companies often face high risks due to the nature of drug development, clinical trials, and regulatory approvals, which can significantly impact financial performance.
Key Players & Entities
- Alector, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- GSK (company) — Mentioned in relation to a member
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20250508.
What is Alector, Inc.'s Standard Industrial Classification code?
Alector, Inc.'s SIC code is 2836, categorized under Biological Products (No Diagnostic Substances).
What is the business address of Alector, Inc.?
Alector, Inc.'s business address is 131 Oyster Point Blvd., Suite 600, South San Francisco, CA 94080.
Are there any specific financial instruments or agreements mentioned with dates?
Yes, the filing references 'CashPledgedAgreementMember' as of 2024-12-31 and 'GskMember' on 2021-08-17, among other date-specific financial disclosures.
From the Filing
0000950170-25-066987.txt : 20250508 0000950170-25-066987.hdr.sgml : 20250508 20250508161517 ACCESSION NUMBER: 0000950170-25-066987 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 25926300 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 10-Q 1 alec-20250331.htm 10-Q 10-Q 0001653087 false Q1 http://fasb.org/us-gaap/2024#OperatingExpenses --12-31 http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001653087 alec:GskMember 2024-01-01 2024-03-31 0001653087 alec:CashPledgedAgreementMember 2024-12-31 0001653087 alec:GskMember 2021-08-17 2021-08-17 0001653087 us-gaap:OverAllotmentOptionMember 2024-01-19 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001653087 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2024-01-01 2024-03-31 0001653087 alec:CertificateOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001653087 us-gaap:CommonStockMember 2025-03-31 0001653087 2024-12-31 0001653087 us-gaap:RetainedEarningsMember 2024-12-31 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001653087 us-gaap:CommonStockMember 2024-12-31 0001653087 alec:CashEquivalentsAndMarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 us-gaap:CommonStockMember 2024-03-31 0001653087 2025-05-02 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001653087 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001653087 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001653087 alec:GskMember 2022-01-01 2022-01-31 0001653087 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001653087 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001653087 alec:GskMember 2021-07-01 2021-07-01 0001653087 alec:GskMember 2025-03-31 0001653087 alec:GskMember srt:MaximumMember 2025-03-31 0001653087 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001653087 2025-03-07 2025-03-07 0001653087 2023-12-31 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001653087 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001653087 2018-06-30 0001653087 2024-01-01 2024-03-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001653087 2024-03-31 0001653087 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2025-01-01 2025-03-31 0001653087 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySe